Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
13.01
-0.02 (-0.15%)
Oct 5, 2026, 9:30 AM EDT - Market open
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $2.96M in the quarter ending June 30, 2026, a decrease of -89.54%. This brings the company's revenue in the last twelve months to $29.37M, down -75.95% year-over-year. In the year 2025, Arcturus Therapeutics Holdings had annual revenue of $82.03M, down -46.14%.
Revenue (ttm)
$29.37M
Revenue Growth
-75.95%
P/S Ratio
12.61
Revenue / Employee
$264,577
Employees
111
Market Cap
369.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 82.03M | -70.28M | -46.14% |
| Dec 31, 2024 | 152.31M | -14.49M | -8.69% |
| Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
| Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
| Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
| Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
| Dec 31, 2019 | 20.79M | 5.04M | 31.97% |
| Dec 31, 2018 | 15.75M | 2.76M | 21.20% |
| Dec 31, 2017 | 13.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Enanta Pharmaceuticals | 65.26M |
| Fennec Pharmaceuticals | 59.22M |
| C4 Therapeutics | 35.04M |
| Orchestra BioMed Holdings | 31.98M |
| Prelude Therapeutics | 22.42M |
| Surrozen | 11.51M |
| Opus Genetics | 9.86M |
ARCT News
- 11 days ago - Arcturus Therapeutics price target lowered to $20 from $23 at BTIG - TheFly
- 11 days ago - Arcturus Therapeutics upgraded to Buy from Neutral at Citi - TheFly
- 11 days ago - Arcturus Therapeutics upgraded to Buy from Neutral at Citi - TheFly
- 11 days ago - Arcturus Therapeutics Holdings Transcript: Status update - Transcripts
- 11 days ago - Arcturus Therapeutics Holdings Press release: Status update - Filings
- 11 days ago - Arcturus Therapeutics Holdings Slides: Status update - Filings
- 11 days ago - Arcturus Therapeutics announces interim OTC deficiency Phase 2 results - TheFly
- 11 days ago - Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform - Business Wire